

This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|---------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cancer | | | | |
| Cancer | DNA | <p>Mouse studies have identified a class of platinum(IV) complexes that could be useful for treating cancer with fewer side effects than approved platinum-based chemotherapeutics. In a mouse model of leukemia, the lead platinum(IV) complex increased survival compared with vehicle. In a mouse model of colorectal cancer, the platinum(IV) complex decreased tumor growth with potency comparable to that of oxaliplatin. In both mouse models, the platinum(IV) complex was well tolerated and did not cause fatigue or weight loss at all doses tested. Next steps could include evaluating the lead platinum(IV) analog in solid tumor models.</p> <p>Oxaliplatin is a generic platinum(II) chemotherapeutic.</p> <p>SciBX 7(33); doi:10.1038/scibx.2014.980 Published online Aug. 28, 2014</p> | Patent and licensing status unavailable | <p>Varbanov, H.P. <i>et al.</i> <i>J. Med. Chem.</i>; published online July 17, 2014; doi:10.1021/jm500791c</p> <p>Contact: Hristo P. Varbanov, University of Vienna, Vienna, Austria e-mail: hristo.varbanov@univie.ac.at</p> |